Eitan Medical, an infusion therapy and drug delivery company continuum, has opened its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medical’s production scale of its Pharmaceutical Solutions division.
Bacho Shutterstock
378954325
Concept of a business premise deal
The facility will manufacture the Sorrel wearable drug delivery platform across multiple device configurations, including Sorrel vial- and cartridge-based wearable injectors, pre-filled and pre-loaded in primary containers up to 50ml, as well as small volume on-body injectors.
Oded Peres, vice president of operations at Eitan Medical, said: “Having on-site manufacturing capabilities enables tight alignment between our R&D, engineering, quality and manufacturing teams and gives us the agility to implement innovations and new product features rapidly. With multiple cleanrooms, production lines and automated testing stations, we can provide quality assurance for every device that passes through our lines.”
The new facility comprises 410 square meters (4413 sq. ft.) with two ISO-7 cleanrooms, as well as 50 square meters (538 sq. ft.) of supporting areas. Two semi-automated production lines incorporate both fully and semi-automated technologies and processes, including, ultrasonic machines, duckbill dispensing robots, high-end pressure and leakage testers, heat staking stations with automated vision control and functional testers with high resolution needle vision inspection and needle lubrication. The increased production capacity for Sorrel devices will support Eitan Medical’s pharmaceutical partners working on feasibility projects, joint development, and clinical studies, as well as commercial implementation. The facility also features manual production lines to support the increased demand from Eitan Medical’s customers and allows for multiple products and customer lines to be manufactured simultaneously.
Dr. Andrei Yosef, general manager of pharmaceutical solutions at Eitan Medical, said: “The manufacturing lines significantly improve our ability to support customers and meet increased market demand, while maintaining full control and quality of our devices. We have multiple pharmaceutical partners looking to utilize our Sorrel wearable drug delivery platform and our increased production capacity will enable us to meet this increasing demand.”
